The antihyperlipidemic activities of 4(3H) quinazolinone and two halogenated derivatives in rats

Lipids in Health and Disease

Volumn 4, Issue , 2005, Pages

  Refaie, Fawzia M ^a   Esmat, Amr Y ^a   Gawad, Soad M Abdel ^b   Ibrahim, Aida M ^c   Mohamed, Mona A ^b  

^a Ain Shams University   (Egypt)

^b Assiut Branch   (Egypt)

^c AL AZHAR UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

6 IODO 2 METHYL 4(3H) QUINAZOLINONE; 6,8 DIBROMO 2 METHYL 4(3H) QUINAZOLINE; ANTILIPEMIC AGENT; BEZAFIBRATE; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; QUINAZOLINONE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; HYPERCHOLESTEROLEMIA; INTESTINE; MALE; NONHUMAN; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BEZAFIBRATE; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL, DIETARY; DIABETES MELLITUS, EXPERIMENTAL; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MALONDIALDEHYDE; QUINAZOLINES; QUINAZOLINONES; RATS;

ANIMALIA;

EID: 27744574330     PISSN: 1476511X     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-4-22     Document Type: Article

References (39)

1. Habib NS, Ismail KA, El-Tombary AA, Abd El-Aziem T: Antilipidemic agents, Part IV: Synthesis and antilipidemic testing of some heterocyclic derivatives of hexadecyl and cyclohexyl hemisuccinate esters. Pharmazie 2000, 55:495-499.
2. Fuster V, Alexander PW, O'Rourke RA, Roberts R, King SB, Wellens HJ: Atherogenesis and its determinants. In Hurst's the heart Volume 3. 10th edition. New York, Mc Graw-Hill; 2001:1065.
3. Devlin T: Textbook of biochemistry with clinical correlations 3rd edition. New York, Wiley-Liss Inc; 1995:376-381.
4. McNamara DJ: Dietary cholesterol and atherosclerosis. Biochim Biophys Acta 2000, 1529:310-320.
5. Krentz AJ: Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 2003, 5:19-27.
6. Koschinsky ML, Marcoina SM: The relationship between lipoprotein alpha and the complications of diabetes mellitus. Acta Diabet 2003, 40:65-76.
7. Kunes J, Bazant J, Pour M, Waisser K, Slosarek M, Janota J: Quinazoline derivatives with antitubercular activity. IL Farmaco 2000, 55:725-729.
8. Magnus NA, Confalone PN, Storace L, Patel M, Wood CC, Davis WP, Parsons RL: General scope of 1,4-Diasteoselective additions to a 2(3H)- quinazolinone: Practical preparation of HIV therapeutics. J Org Chem 2003, 68:754-61.
9. Jantova S, Urbancikova M, Maliar T, Mikuldsova M, Rauko P, Cipak L, Kubikova J, Stankovsky S, Spirkova K: Biological activity of some 4-anilinoquinazolines: cytotoxic, genotoxic and antiprotease effects, induction of necrosis and changes of actin cytoskeleton. Neoplasm 2001, 48:52-60.
10. Chern J, Tao P, Wang K, Gutcait A, Liu S, Yen M, Chien S, Rong J: Studies on quinazolines and 1, 2, 4-benzothiadiazine 1, 1-dioxides. Synthesis and pharmacological evaluation of tricyclic fused quinazolines and 1,2, 4-benzothiadiazine 1,1,-dioxides as potential alpha 1-adrenoceptor antagonists. J Med Chem 1998, 41:3128-3141.
11. Santagati A, Modica M, Santagati M, Cutuli VM, Mangano NG, Caruso A: Synthesis and pharmacological screening of 1, 3, 4-thiadiazino [2,3-b]quinazoline derivatives. Pharmazie 2000, 55:737-739.
12. Kurogi Y, Inoue Y, Tsutsumi K, Nakamura S, Nagao K, Yoshitsugu H, Tsuda Y: Synthesis and hypolipidemic activities of novel 2-(4-[(diethoxyphosphoryl) methyl]phenyl) quinazolines and 4(3H)- quinazolinones. J Med Chem 1996, 39:1433-37.
13. Parkanyi C, Schmidt DS: Synthesis of 5- chloro -2- methyl- 3- (5-methylthiazol -2-yl) - 4(3H) quinazolinone and related compounds with potential biological activity. J Heterocyclic Chem 2000, 37:725-729.
14. Paget GE, Barnes JM: Evaluation of drug activities. In Pharmacometrics Volume 1. Edited by: Laurence DR, Bacharach AL. London, Academic Press; 1964:50.
15. Maillard J, Benard M, Vincent M, Tri V, Jolly R: Dérivés de la (3H) quinazolinone-4-doués de propiétés anti-inflammatoire. Chimie Thérape 1967, 3:202-12.
16. Seki K, Watanabe T, Suga T: Influence of the new antihypertensive drug, SM-2470 (a quinazoline derivative), on cholesterol metabolism in rats. J Pharm Pharmacol 1987, 39:904-910.
17. Sheweita SA, Newairy AA, Mansour HA, Youssif MI: Effect of some hypoglycemic herbs on the activity of phase I and II drug - metabolizing enzymes in alloxan- induced diabetic rats. Toxicology 2002, 174:131-39.
18. Trinder P: Determination of glucose in blood using glucose oxidase with an alternative oxygen receptor. Ann Clin Biochem 1969, 6:24-28.
19. Zlatkis A, Zak B, Boyle AJ: A new method for the direct determination of serum cholesterol. J Lab Clin Med 1953, 41:486-92.
20. Jacobs NJ, Van Denmark PJ: The purification and properties of the alpha-glycerophosphate-oxidizing enzyme of Streptococcus faecalis 10 C1. Arch Biochem Biophys 1960, 88:250-55.
21. Knight JA, Anderson S, Rawle JM: Chemical basis of the sulfophospho-vanillin reaction of estimating total serum lipids. Clin Chem 1972, 18:199-204.
22. Assmann G, Schriewer H, Schmitz G, Hagele EO: Quantification of high density lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2. Clin Chem 1983, 29:2026-2030.
23. Kerscher L, Schiefer S, Draeger B, Maier J, Ziegenhorn J: Precipitation methods for the determination of LDL-cholesterol. Clin Biochem 1985, 18:118-125.
24. Freidwald WT, Levy RJ, Fredrickson DS: Estimation of the concentration of the preparative ultracentrifuge. Clin Chem 1972, 18:499-509.
25. Bok SH, Lee SH, Park YB, Bae KH, Son KH, Jeong TS, Choi MS: Plasma and hepatic cholesterol and hepatic activities of 3-hydroxy-3-methyl-glutaryl-CoA reductase and acyl CoA: Cholesterol transferase is lower in rats fed citrus pee extract or a mixture of citrus bioflavonoids. J Nutr 1999, 129:1182-85.
26. Gottfried SP, Rosenberg B: Improved manual spectrophotometric procedure for determination of serum triglycerides. Clin Chem 1973, 19:1077-1080.
27. Esterbauer H, Cheeseman KH: Determination of aldehyde lipid peroxidation products: Malonaldehyde and 4-hydroxynonenal. Methods in Enzymology 1990, 186:407-10.
28. Williams B: Biostatistics, Chapman & Hall, London; 1993.
29. Wu H, Johnston P, Seu W, Hollenbeck CB, Jeng CY, Goldfine ID, Chen YD, Reaven GM: Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990, 13:1-10.
30. Sellei C, Hardt E, Nemeth L: "Chemotherapy of neoplastic diseases" Budapest, Akademiai Kiado, The Publishing House of the Hungarian Academy of Science; 1970:35-45.
31. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F: Experimental antitumor activity of taxotere (RP56976, NSC 628503), a taxol analogue. Cancer Res 1991, 51:4845-4852.
32. Feron VJ, de Groot AP, Spanjers MT, Til HP: An evaluation of the criterion "organ weight" under conditions of growth retardation. Food Cosmet Toxicol 1973, 11:85-94.
33. Gallo L, Bennett C, Myers S, Vanouny G: Cholesterol absorption in rat intestine: Role of cholesterol esterase and ACAT. J Lipid Res 1984, 25:604-12.
34. Park YB, Jeon SM, Byun SJ, Kim HS, Choi MS: Absorption of intestinal free cholesterol is lowered by supplementation of Areca catechu L. extract in rats. Life Sci 2002, 70:1849-1859.
35. Nelson DL, Cox MM: Lehninger Principles of Biochemistry 3rd edition. New York, Worth Publisher; 2000:800-805.
36. Yano M, Inoune M, Maehata F, Shiba T, Yamakado M, Hirabayashi Y, Taniyama M, Suzuki S: Increased electronegative charge of serum low density lipoprotein in patients with diabetes mellitus. Clin Chim Acta 2004, 340:93-98.
37. Peng IH, Sheu JR, Chern JW, Lee YM, Yen MH: Antihypertensive and hypolipidaemic effects of DC-015, a novel potent and specific α1 adrenoceptor antagonist: Comparison with prazocin in spontaneously hypertensive rats. J Biomed Sci 1996, 3:108-116.
38. Carr TP, Parks JS, Rudel LL: Hepatic ACAT activity in African green monkeys is highly correlated to plasma LDL cholesteryl esters enrichment and coronary artery atherosclerosis. Atheroscler Thromb 1992, 12:1274-83.
39. Carr TP, Hamilton RL, Rudel LL: ACAT inhibitors decrease secretion of CE and apo B by perfused livers of African green monkeys. J Lipid Res 1995, 36:25-36.